• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


H&T Presspart Low GWP Banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Business

Upsher-Smith launches Tosymra nasal spray in the US

Upsher-Smith has announced the US launch of Tosymra sumatriptan nasal spray. The FDA approved Tosymra for the treatment of migraine with or without aura in January 2019, and Upsher-Smith acquired US rights to the nasal spray from Promius Pharma in June 2019. The Tosymra formulation uses Intravail transmucosal absorption enhancement technology and is delivered via … [Read more...] about Upsher-Smith launches Tosymra nasal spray in the US

Lannett makes deal for distribution of generic Advair in US

Lannett said that it has signed a US distribution agreement for rights to Respirent Pharmaceuticals' generic Advair Diskus. The agreement would begin after FDA approval and would continue for 10 years after distribution begins. Lannett said that it would pay an unspecified upfront payment and future milestones and that it would receive a portion of net profits during … [Read more...] about Lannett makes deal for distribution of generic Advair in US

Currax Pharmaceuticals acquires North American rights to Onzetra Xsail

Currax Pharmaceuticals has acquired US, Canadian, and Mexican rights to Onzetra Xsail intranasal dry powder sumatriptan from OptiNose, which announced that the license agreement includes a $4.8 million upfront payment, plus a 10% royalty on net sales over $3 million in 2020 and a $1 million milestone payment "subject to the achievement of a specified regulatory … [Read more...] about Currax Pharmaceuticals acquires North American rights to Onzetra Xsail

Dance Biopharm changes its name to Aerami Therapeutics, moves headquarters, adds to pipeline

Dance Biopharm has announced a name change, saying that the company will now be known as Aerami Therapeutics. The company, which is developing the Dance 501 insulin SMI, said that it is also moving its headquarters from San Francisco, CA to Durham, NC, USA and is expanding its pipeline. The company recently presented results from the Phase 2 SAMBA 04 study of … [Read more...] about Dance Biopharm changes its name to Aerami Therapeutics, moves headquarters, adds to pipeline

Lachesis Biosciences gets grant for commercialization of nasal spray for dementia

The Australian government has awarded Victoria-based Lachesis Biosciences AUS$438,000 for commercialization of the company's rivastigmine nasal spray for the treatment of dementia in patients with Alzheimer's Disease. The Accelerating Commercialisation grant is designed to"help businesses turn good ideas into marketable products through activities such as trials, … [Read more...] about Lachesis Biosciences gets grant for commercialization of nasal spray for dementia

TerrAscend to distribute Syqe inhaler in Canada

Canadian-based cannabis company TerrAscend has acquired exclusive distribution rights to Syqe Medical's Syqe medical cannabis inhaler in Canada, the companies announced. The Syqe inhaler, which uses cartridges loaded with medical cannabis plant material, has been available to patients for the treatment of pain in Israel since June 2019; previously, the inhaler was … [Read more...] about TerrAscend to distribute Syqe inhaler in Canada

Judge increases award to Vectura in Ellipta case

Ruling on post-trial motions in a case in which a jury found in May 2019 that GSK had willfully infringed on a Vectura patent covering Ellipta, the presiding judge has upheld the jury's award of $89.7 million in damages to Vectura and has added an additional $10.5 million in damages based on GSK's continued infringement. The original award was based on 3% … [Read more...] about Judge increases award to Vectura in Ellipta case

Optinose announces $150 million debt financing from Pharmakon Advisors

Intranasal drug developer Optinose announced that it has issued $80 million in senior secured notes as part of a $150 million debt financing agreement with Pharmakon Advisors. The company plans to issue another $30 million in notes by mid-February 2020, "subject to the achievement of minimum Xhance revenues and certain other conditions." Optinose's Xhance fluticasone … [Read more...] about Optinose announces $150 million debt financing from Pharmakon Advisors

Satsuma looks to raise $82.5 million in IPO for continued development of intranasal DHE

Satsuma Pharmaceuticals has announced an underwritten initial public offering of 5,500,000 shares of its common stock at $15.00 per share, with expected gross proceeds of $82.5 million. The underwriters of the offering also get a 30-day option to purchase additional shares of common stock (up to a total of 825,000 shares) at the same price. The company's common stock … [Read more...] about Satsuma looks to raise $82.5 million in IPO for continued development of intranasal DHE

Dance Biopharm announces deal with DarioHealth

Inhaled insulin developer Dance Biopharm announced that it has signed an agreement with DarioHealth to integrate its smart soft mist inhaler into DarioHealth's digital platform. The integration, which will allow patients using the SMI to get usage data in real time through a mobile app, is expected to be completed in time for upcoming clinical trials and would be … [Read more...] about Dance Biopharm announces deal with DarioHealth

  • « Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 54
  • Page 55
  • Page 56
  • Page 57
  • Page 58
  • Interim pages omitted …
  • Page 152
  • Next Page »

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Proveris_180x150a
    Bespak Leading the Green Transition banner
    © 2025 OINDPnews